Saving More Lives
Moffitt Cancer Center's unparalleled research focuses on cutting-edge discoveries that are rapidly translated into improved diagnostic, preventative, and therapeutic advancements, which are then shared with providers throughout the state and the country.
As Florida’s first National Cancer Institute-designated Comprehensive Cancer Center and one of only 30 leading cancer centers in the U.S. participating in the National Comprehensive Cancer Network, Moffitt is at the very forefront of cancer centers worldwide.
Equipped with top research and care experts working side-by-side, Moffitt is uniquely positioned to revolutionize cancer treatment, elevate care and save more lives.
A Beacon for Cancer Care in FL
-
67 Counties Served
In the last year, Moffitt has served patients from all 67 of Florida's counties. We've seen patients from all 50 states and 130+ countries.
-
19,501
Patients participated in clinical trials and nontherapeutic studies last year.
-
660+
Unique articles published by Moffitt physicians & scientists last year.
-
52
Investigative new drug applications submitted to the FDA in the past year.
-
17
U.S. patents issued in the past year.
Superior Cancer Survival Rates
Moffitt is proud of the survival rates we deliver for cancer patients in Florida. Our outcome statistics are derived from The Surveillance, Epidemiology, and End Results (SEER) Program, a trusted source supported by the National Cancer Institute’s Division of Cancer Control and Population Sciences.
- Bladder Cancer - 162% Higher Survival Rates
- Breast Cancer - 63% Higher Survival Rates
- Cervical Cancer - 71% Higher Survival Rates
- Colorectal Cancer - 139% Higher Survival Rates
- Liver Cancer - 216% Higher Survival Rates
- Lung Cancer - 140% Higher Survival Rates
- Melanoma - 64% Higher Survival Rates
- Mesothelioma - 134% Higher Survival Rates
- Ovarian Cancer - 39% Higher Survival Rates
- Pancreatic Cancer - 326% Higher Survival Rates
- Prostate Cancer - 66% Higher Survival Rates
- Stomach Cancer - 126% Higher Survival Rates
Food as Medicine
Revolutionary advances in our understanding of cancer biology and metabolism have fueled new research on the role of diet to help prevent cancer, make cancer treatments work better, and reduce treatment toxicity.
With a $10 million investment in the Population Engagement and Research Lab (PEARL), Moffitt is conducting nutritional, metabolomic, and behavioral studies overseen by talented scientists with expertise in energy balance and cancer metabolism. One of only three such facilities in the nation, PEARL is equipped with a research kitchen to enable precision feeding studies which allow investigators to understand how specific diets impact specific drivers of cancer.
Improving Cancer Outcomes with Diet
Highlights from the current research portfolio:
- Green tea catechins to fight prostate cancer (clinical trial)
- DINING study to evaluate an anti-inflammatory diet for colorectal cancer prevention
- Evaluate the effects of two-week ketogenic diet on immune function to improve the efficacy of CAR T-cell therapy (pilot clinical trial)
- Effects of ketogenic diet on efficacy of immune checkpoint inhibitor therapy (pilot clinical tria
- Effects of fermented foods on the gut microbiome and treatment response in colorectal and lung cancer patients (pilot clinical trial)
- A clinical trial of an easy-to-swallow, high protein, meal-replacement for head and neck cancer patients
- MIND-BC trial to evaluate whether a Mediterranean DASH diet to can cognitive function after chemotherapy in breast cancer survivors
- The Moffitt Table™ cookbook which contains nutrient-dense meals that are both preventative and beneficial for people diagnosed with cancer
Clinical Care Often Starts in a Lab
Learn about a few of the departments who are conducting studies that will change the way patient care is delivered in the future.
High Volume Fosters High Expertise
Our multispecialty medical professionals are dedicated to the treatment and research of cancer, and cancer only. By tailoring individualized care plans to unique patient needs, Moffitt is aiming to achieve the best outcome for each patient to save more lives. In the past year Moffitt saw:
-
668,000+
Outpatient Visits
-
97,000+
Unique Patients Seen
-
13,000+
Surgical Cases
-
30,000+
New Patients
Delivering Breakthroughs to Patients First
Moffitt’s unparalleled research focuses on cutting-edge discoveries that can rapidly translate into improved diagnostic, preventative and therapeutic advancements. Some of our 'firsts' include:
-
First to introduce Proteus®ONE Proton Therapy System to Tampa Bay
Moffitt’s therapy system, supplied by IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, is the world's most advanced form of cancer-killing technology. Moffitt will be one of the few top cancer centers in the U.S. with state-of-the-art proton therapy technology that has received clearance from the Food and Drug Administration. This positions Moffitt at the forefront of cancer care and offers patients access to highly effective minimally invasive treatments and produce better outcomes.
-
Leader for Cell & Targeted Therapies
Cellular immunotherapy is an innovative treatment approach that harnesses the body’s own immune system to fight cancer. Moffitt played a crucial role in the landmark 2017 FDA approval of Yescarta. The ZUMA-1 clinical trial that led to this approval was co-led by Moffitt's Dr. Fredrick Locke,MD and solidified Moffitt's position at the forefront of CAR T therapy.
Moffitt offers several types of cellular immunotherapy, including (CAR) T-cell therapy, (TCR) therapy and (TIL) therapy. These novel treatments are helping transform the landscape for many current and future cancer patients. Moffitt is the first cancer treatment center in the world to have treated over 1,500 patients with CAR-T therapy.
-
First in U.S. to Offer New Lung Cancer Therapy
Moffitt was the first U.S. provider to treat a patient with extensive-stage small cell lung cancer (SCLC) following FDA of tarlatamab. The FDA approved the drug on May 16, 2024. This marked a significant advancement in treating SCLC, the deadliest form of lung cancer, with a five-year survival rate of 8% for women and 6% for men.
-
First in the World for FDA Approved Gene Therapy for Synovial Sarcoma
Moffitt is proud to be the first authorized treatment center in the world for the recently FDA-approved TCR therapy for metastatic/unresectable synovial sarcoma. This development, led by Moffitt's Dr. Mihaela Druta, MD,is groundbreaking for patients with synovial sarcoma, a rare soft tissue cancer. Synovial sarcoma, which typically affected tissues around joints, was challenging to treat due to tumor growth and progression. However, this new gene therapy promised to change the treatment landscape by harnessing the body’s immune cells to target the cancer.
-
First FDA Approved Cell Therapy for Solid Tumors
The National Cancer Institute has been studying TIL therapy since the 1980s. After Moffitt researchers visited the institute to learn the protocol in 2009, Moffitt became the first cancer center outside of the institute to offer TIL to melanoma patients. This work, spearheaded by Dr. Amod Sarnaik, MD, led to the 2024 FDA approval of the first TIL therapy for advanced melanoma.
Now that the first TIL product is approved, Moffitt experts are exploring ways to optimize the treatment, and discovering opportunities to apply this groundbreaking treatment to other cancer types.
Attracting Top Talent to Florida
-
~10,000
Team Members
-
400+
Physician Faculty Members
-
190+
Research Faculty
-
440+
Advanced Practice Providers
Moffitt has almost 10,000 team members living and working in Tampa Bay and across Florida. Moffitt Medical Group is Florida’s largest multispecialty medical group practice dedicated to cancer treatment. With hundreds of board-certified physicians and advanced practice professionals who have dedicated their careers to cancer care, Moffitt providers are uniquely trained in cancer and bring exceptional expertise from treating a high volume of complex cases.
As one of the nation's top-ranked cancer hospitals, Moffitt attracts highly qualified healthcare providers and researchers. The number of providers employed at Moffitt has grown by 40% in the past five years. Many of our oncologists are physician scientists, conducting research to develop new and more effective therapies to broaden the range of services we offer.
Teaching the Next Generation of Physicians and Scientists in Oncology
Education and training is a fundamental part of Moffitt's core mission. We provide numerous education opportunities for physicians and other healthcare professionals, international visiting scholars, postdoctoral, graduate and undergraduate college and pre-college students.
Moffitt is an ACGME- accredited institution and serves as an academic training affiliate of the University of South Florida Morsani College of Medicine. Moffitt's research enterprise offers training and education in numerous areas key in the fight against cancer including Postdoctoral Training, Graduate Training, Undergraduate and Visiting Scholars and Pre-College Programs.
In 2024, Moffitt trained over 500 medical students, 400 residents, and more than 200 oncology fellows.
-
550+
Research Trainees Last Year
-
1,200+
Graduate Medical Education Trainees Last Year
The End of Cancer Begins Here®
We've spent decades building the kind of enriched, collegial, and collaborative environment required to perform outstanding cancer research and educate the next generation. The Research Institute within Moffitt boasts five research programs, four centers of excellence, five research departments, 15 academic clinical departments, and even more divisions, each carrying out critical elements in the fight against cancer.
